Some of the losses seen by insiders who purchased CN¥87.4m worth of Cryofocus Medtech (Shanghai) Co., Ltd. (HKG:6922) shares over the past year were recovered after the stock increased by 15% over the past week. However, the purchase is proving to be a costly gamble, since losses made by insiders have totalled CN¥47m since the time of purchase.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
Check out our latest analysis for Cryofocus Medtech (Shanghai)
The Last 12 Months Of Insider Transactions At Cryofocus Medtech (Shanghai)
The insider Jianhui Wu made the biggest insider purchase in the last 12 months. That single transaction was for HK$43m worth of shares at a price of HK$17.00 each. That means that even when the share price was higher than HK$7.91 (the…
